The Division of Hematology/Oncology is a part of the Department of Medicine and the Cancer Therapy & Research Center (CTRC), a top-tier cancer center with the prestigious National Cancer Institute designation. The Division encompasses three major Sections: Solid Tumors Oncology, Hematology and Stem Cell Transplantation, and Basic Sciences. We strongly believe that the care of patients with cancer is best delivered in a multidisciplinary approach by a team of healthcare professionals who have sufficient expertise and experience necessary to provide excellent care. To address this major need, we have developed Specialized Clinics and research programs with teams of expert clinicians and researchers. Clinical Disease Site Teams and Translational Research Working Groups aim at developing novel, personalized therapies for cancer. Our Phase I program is associated with the Institute for Drug Development (IDD), a renowned center for the development of innovative cancer therapies.

The facilities of the Division include Hematology/Oncology outpatient clinics at the CTRC and a state-of-the-art infusion center for administration of cancer therapies, including standard and investigational therapies, with capabilities of pharmacokinetic sampling, inpatient services in association with University Hospital, St. Luke’s/Baptist Hospital and Methodist Hospital, and several laboratory facilities dedicated to cancer research.

Our ACGME accredited Hematology/Oncology Fellowship program educates fellows in the field of academic medicine, including both clinical and basic science related to cancer and blood disease. Our fellows have ample opportunities for training at the CTRC, and affiliated hospitals, including the Audie L. Murphy Veteran Affairs Hospital.

We hope to have addressed your questions about our growing Division. We are poised to excel and offer the best clinical services, make breakthrough scientific discoveries, develop novel therapies that will impact on patient outcome, and educate the next generation of experts.

With respect,

Anand Karnad, M.D.,

Division Chief of Hematology/Oncology